Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure
Clinical trial NCT04144348 · COMPLETED
Trial details
- NCT number
- NCT04144348
- Sponsor
- ModernaTX, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-11-04
- Primary completion
- 2022-12-20
- Enrollment
- 51
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.